Skip to main content
Figure 3 | Journal for ImmunoTherapy of Cancer

Figure 3

From: Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

Figure 3

A 61-year-old male with metastatic melanoma. Contrast-enhanced CT scan of the chest at baseline (A) demonstrate a lobulated right lower lobe mass measuring 37 mm and 54.3 HU (A, arrow). The follow-up scan (B) at 11.4 weeks of ipilimumab and bevacizumab therapy demonstrated the lesion measuring 36 mm and 44.4 HU (B, arrow). While the percent decrease of diameter was only 2%, CT density decreased by 18% comparing to baseline, meeting the Choi response criteria.

Back to article page